

# Aaron T Wecksler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5291363/publications.pdf>

Version: 2024-02-01

26  
papers

1,030  
citations

471509

17  
h-index

552781

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1576  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Monoclonal antibody targeting the Î²-barrel assembly machine of <i>Escherichia coli</i> is bactericidal. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3692-3697.                      | 7.1  | 149       |
| 2  | Synthesis and Structure-Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase. Journal of Medicinal Chemistry, 2011, 54, 3037-3050.                        | 6.4  | 148       |
| 3  | Structural basis for dual-mode inhibition of the ABC transporter MsbA. Nature, 2018, 557, 196-201.   | 27.8 | 125       |
| 4  | Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3732-3737.  | 2.2  | 87        |
| 5  | Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 100, 38-46.  | 4.3  | 65        |
| 6  | Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biology and Therapy, 2011, 12, 827-836.  | 3.4  | 57        |
| 7  | Mapping the Binding Interface of VEGF and a Monoclonal Antibody Fab-1 Fragment with Fast Photochemical Oxidation of Proteins (FPOP) and Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2017, 28, 850-858. | 2.8  | 51        |
| 8  | A novel p21 attenuator which is structurally related to sorafenib. Cancer Biology and Therapy, 2013, 14, 278-285.  | 3.4  | 44        |
| 9  | Characterizing monoclonal antibody structure by carboxyl group footprinting. MAbs, 2015, 7, 540-552.   | 5.2  | 37        |
| 10 | Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation. Journal of Lipid Research, 2014, 55, 1131-1138.   | 4.2  | 34        |
| 11 | Kinetic and Spectroscopic Studies of N694C Lipoxygenase: A Probe of the Substrate Activation Mechanism of a Nonheme Ferric Enzyme. Journal of the American Chemical Society, 2007, 129, 7531-7537.                                   | 13.7 | 27        |
| 12 | Characterization of ELISA Antibody-Antigen Interaction using Footprinting-Mass Spectrometry and Negative Staining Transmission Electron Microscopy. Journal of the American Society for Mass Spectrometry, 2018, 29, 961-971.        | 2.8  | 27        |
| 13 | Mapping of Fab-1:VEGF Interface Using Carboxyl Group Footprinting Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2015, 26, 2077-2080.   | 2.8  | 24        |
| 14 | Native MS and ECD Characterization of a Fab-Antigen Complex May Facilitate Crystallization for X-ray Diffraction. Journal of the American Society for Mass Spectrometry, 2016, 27, 1139-1142.  | 2.8  | 22        |
| 15 | Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1. Bioorganic and Medicinal Chemistry, 2009, 17, 6534-6539.  | 3.0  | 21        |
| 16 | Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity. Journal of Biological Chemistry, 2021, 297, 100826.   | 3.4  | 19        |
| 17 | Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. MAbs, 2020, 12, 1802135.  | 5.2  | 18        |
| 18 | Photodisruption of the Structurally Conserved Cys-Cys-Trp Triads Leads to Reduction-Resistant Scrambled Intrachain Disulfides in an IgG1 Monoclonal Antibody. Molecular Pharmaceutics, 2018, 15, 1598-1606.                          | 4.6  | 17        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Biological evaluation of a novel sorafenib analogue, t-CUPM. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 161-171.   | 2.3 | 14        |
| 20 | Inhibition of mutant KrasG12D -initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t -CUPM. <i>Cancer Letters</i> , 2016, 371, 187-193.    | 7.2 | 12        |
| 21 | Optimizing Hydroxyl Radical Footprinting Analysis of Biotherapeutics Using Internal Standard Dosimetry. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 1563-1571. | 2.8 | 8         |
| 22 | Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody. <i>MAbs</i> , 2022, 14, 2028337.   | 5.2 | 8         |
| 23 | Characterizing monoclonal antibody structure by carbodiimide/GEE footprinting. <i>MAbs</i> , 2014, 6, 1486-1499.  | 5.2 | 7         |
| 24 | Current Trends in Biotherapeutic Higher Order Structure Characterization by Irreversible Covalent Footprinting Mass Spectrometry. <i>Protein and Peptide Letters</i> , 2019, 26, 35-43.     | 0.9 | 5         |
| 25 | Novel sorafenib-based structural analogues. <i>Anti-Cancer Drugs</i> , 2014, 25, 433-446.   | 1.4 | 3         |
| 26 | Development of Software Workflow for the Rapid Detection of Cross-Linked Dipeptides. <i>Journal of the American Society for Mass Spectrometry</i> , 2022, 33, 598-602.                      | 2.8 | 1         |